Cargando…

Current State of Clostridium difficile Treatment Options

Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Venugopal, Anilrudh A., Johnson, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388023/
https://www.ncbi.nlm.nih.gov/pubmed/22752868
http://dx.doi.org/10.1093/cid/cis355
_version_ 1782237131006017536
author Venugopal, Anilrudh A.
Johnson, Stuart
author_facet Venugopal, Anilrudh A.
Johnson, Stuart
author_sort Venugopal, Anilrudh A.
collection PubMed
description Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment of mild to moderate CDI and vancomycin for severe CDI. Results from small clinical trials suggest that nitazoxanide and teicoplanin may be alternative options to standard therapies, whereas rifaximin has demonstrated success in uncontrolled trials for the management of multiple recurrences. Anecdotal reports have also suggested that tigecycline might be useful as an adjunctive agent for the treatment of severe complicated CDI. Reports of resistance will likely limit the clinical use of fusidic acid and bacitracin and, possibly, rifaximin if resistance to this agent becomes widespread. Treatment of patients with multiple CDI recurrences and those with severe complicated CDI is based on limited clinical evidence, and new treatments or strategies are needed.
format Online
Article
Text
id pubmed-3388023
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-33880232012-08-01 Current State of Clostridium difficile Treatment Options Venugopal, Anilrudh A. Johnson, Stuart Clin Infect Dis Supplement Articles Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment of mild to moderate CDI and vancomycin for severe CDI. Results from small clinical trials suggest that nitazoxanide and teicoplanin may be alternative options to standard therapies, whereas rifaximin has demonstrated success in uncontrolled trials for the management of multiple recurrences. Anecdotal reports have also suggested that tigecycline might be useful as an adjunctive agent for the treatment of severe complicated CDI. Reports of resistance will likely limit the clinical use of fusidic acid and bacitracin and, possibly, rifaximin if resistance to this agent becomes widespread. Treatment of patients with multiple CDI recurrences and those with severe complicated CDI is based on limited clinical evidence, and new treatments or strategies are needed. Oxford University Press 2012-08-01 /pmc/articles/PMC3388023/ /pubmed/22752868 http://dx.doi.org/10.1093/cid/cis355 Text en Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2012. http://creativecommons.org/licenses/by-nc/2.5/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Articles
Venugopal, Anilrudh A.
Johnson, Stuart
Current State of Clostridium difficile Treatment Options
title Current State of Clostridium difficile Treatment Options
title_full Current State of Clostridium difficile Treatment Options
title_fullStr Current State of Clostridium difficile Treatment Options
title_full_unstemmed Current State of Clostridium difficile Treatment Options
title_short Current State of Clostridium difficile Treatment Options
title_sort current state of clostridium difficile treatment options
topic Supplement Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388023/
https://www.ncbi.nlm.nih.gov/pubmed/22752868
http://dx.doi.org/10.1093/cid/cis355
work_keys_str_mv AT venugopalanilrudha currentstateofclostridiumdifficiletreatmentoptions
AT johnsonstuart currentstateofclostridiumdifficiletreatmentoptions